Abstract 16799: Comparative Cardiovascular Outcomes of GLP-1 Receptor Agonists versus SGLT2 Inhibitors in Patients with Prior Myocardial Infarction and Overweight or Obesity: A Propensity-Matched Analysis
TL;DR
In patients with prior MI and overweight or obesity, GLP-1 RA use was associated with substantially lower risk of MACE and new-onset heart failure than SGLT2i, with consistent benefit across ischemic and pulmonary vascular outcomes and neutral effects on mortality.
Abstract
Introduction: Patients with prior myocardial infarction (MI) and overweight or obesity face high residual risk of recurrent cardiovascular events and heart failure. GLP-1 receptor agonists (GLP-1 RA) and SGLT2 inhibitors (SGLT2i) are widely used in this group, yet their comparative cardiovascular effects are poorly defined. Hypothesis: GLP-1 RA use is associated with lower risk of major adverse cardiovascular events (MACE) and new-onset heart failure than SGLT2i in post-MI patients with overweight or obesity. Methods: Using the TriNetX Global Collaborative Network, we identified adults aged 18 to 85 with prior MI and overweight or obesity who started GLP-1 RA or SGLT2i on or after January 2012, excluding users of the other drug class (Figure 1). Propensity score matching on 50 covariates (demographics, diagnoses, medications, and laboratory values) produced 18,803 well-matched pairs (all standardized differences below 0.02). Co-primary outcomes were MACE (composite of acute MI, ischemic stroke, cardiac arrest, and cardiac arrhythmia) and new-onset heart failure. Secondary outcomes were recurrent MI, ischemic stroke, pulmonary hypertension, atrial fibrillation, and all-cause mortality. Hazard ratios (HR) were estimated using Cox models. Results: Matched cohorts were balanced (mean age 63 years, 61% male, 71% diabetes; median follow-up about 1.5 years). GLP-1 RA was associated with lower risk of MACE (HR 0.75, 95% CI 0.66 to 0.84; 10.6% vs 13.5%) and new-onset heart failure (HR 0.58, 95% CI 0.53 to 0.63; 8.9% vs 15.4%; both p<0.001) (Figure 2). Benefit extended to recurrent MI (HR 0.75), ischemic stroke (HR 0.85), and pulmonary hypertension (HR 0.78; all p<0.05). All-cause mortality (HR 0.95, 95% CI 0.89 to 1.02) and atrial fibrillation (HR 0.91) did not differ significantly, and a negative-control outcome (hip fracture, HR 1.02) confirmed no systematic bias. Conclusion: In patients with prior MI and overweight or obesity, GLP-1 RA use was associated with substantially lower risk of MACE and new-onset heart failure than SGLT2i, with consistent benefit across ischemic and pulmonary vascular outcomes and neutral effects on mortality. These findings support a preferential cardioprotective role for GLP-1 RA and warrant prospective confirmation.